Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orient-11: Sintilimab + Chemotherapy in First-Line Advanced Non-squamous NSCLC
NCT03607539Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sintilimab + Pemetrexed + Platinum with Placebo + Pemetrexed + Platinum (2 arms). Primary endpoint: Progression-Free Survival. Started Aug 2018; status: completed.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03607539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607539.